Navigation Links
Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years
Date:9/25/2011

have hormone receptor-positive tumours. These tumours occur in approximately 75% of breast cancer cases. Tamoxifen has been the "gold standard" hormone treatment for women with early, oestrogen-receptor-positive breast cancer and works by blocking the growth-promoting action of oestrogen on the cancer cells. Aromatase inhibitors, such as letrozole, are newer and alter the function of aromatase, an enzyme involved in oestrogen production. They can be used in sequence with, or as an alternative to tamoxifen for post-menopausal women.

In the BIG 1-98 trial, researchers enrolled 8,010 patients to receive letrozole and tamoxifen either alone or in sequence, with a total of 4,922 patients included in the monotherapy arms of the study.

Efficacy analyses comparing the treatment groups were conducted every two years following the initial report of results, because the patients had a long-term risk of recurrence. This 12-year update shows that, among all 8,010 patients, there were 2,074 relapses and 1,284 deaths, compared with 1,569 relapses and 923 deaths at the ten-year update.

"The data also show that the sequential use of letrozole and tamoxifen (two years of one agent followed by three years of the other) provided similar outcomes compared with five years of letrozole alone for patients who are not at high risk for recurrence," said Prof Gelber.

"The optimal regimen remains an open question in many areas of the world, and this large trial presents definitive results for the treatment of the largest group diagnosed with breast cancer: post-menopausal women with hormone-responsive early breast cancer."

He added: "Letrozole and tamoxifen have different side effects, and clinicians should consider the individual patient's medical history when prescribing treatment. Both agents are considered to be safe, especially in view of the substantial reduction in the risk of recurrence and the improved survival provided by these two e
'/>"/>

Contact: Kay Roche
kayroche@gmail.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Study sheds light on aromatase inhibitor joint pain syndrome
2. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
3. Patients Who Take a Proton-Pump Inhibitor With Medicine to Prevent Blood Clots Are Less Likely to Be Hospitalized for Bleeding Ulcers
4. BRAF inhibitor shows promising preclinical activity against melanoma
5. JAK inhibitor provides rapid, durable relief for myelofibrosis patients
6. Novel biomarker may predict response to new VEGF receptor inhibitor
7. Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
8. PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans
9. JAK inhibitors producing significant response in myelofibrosis patients
10. Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate
11. Combining 2 peptide inhibitors might block tumor growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Many Americans know little about how Ebola is transmitted and ... the United States, a new survey shows. About four ... be a major Ebola outbreak in the United States, and ... will get sick with the deadly virus in the next ... poll. However, those opinions don,t match reality, the Harvard ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... Millennium Treatment Group, a drug ... recently launched a new website. Patients, parents, loved ... now find Millennium Treatment Group at http://www.millenniumtreatmentgroup.com ... at the beginning of July. Everything anyone would ... found on the website. There’s an About Us ...
(Date:8/22/2014)... 22, 2014 Natural Clear Vision , ... restore his own vision from legally blind to perfect 20/20 ... investigative review. , “There is a huge portion of ... everyday function, and most people just think that’s the way ... surgery that can be pretty risky at times,” reports Michaels. ...
(Date:8/22/2014)... Beat Eczema , Susan Clark’s ... natural methods to completely cure the eczema symptoms they ... Shane Michaels, prompting an investigative review. , “Although ... it can still be extremely debilitating and life-altering for ... itching and pain that it causes on the skin ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Millennium Treatment Group Has a New Website 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2
... 1 Misonix, Inc., (Nasdaq: MSON ), a ... Europe is used for the ablation of tumors and worldwide ... of its direct sales channel for the United States, which ... already established, commission based, contract sales organization, the Company has ...
... , KNOXVILLE, Tenn., Sept. ... Joint Commission,s intra-cycle certification, a program that offers an ... provide competent staffing services. This certification follows Spectrum,s third ... in 2008. , , "Healthcare organizations ...
... , , , ... sixth season of the Thrive advertising campaign, with television, radio, print ... the total health of its members and the communities it serves. ... and "Connected" -- illustrate Kaiser Permanente,s leadership in leveraging health information ...
... , PORTLAND, Ore., Sept. 1 ... Award recognizing the Administrator software for its innovative contributions to Senior ... Awards Program is the first awards program of its kind to ... families and care providers. Entries were judged by a distinguished panel ...
... , , HOUSTON, Sept. 1 ... is the first hospital in Houston to feature the CyberKnife((R)), a ... tumors. , , The CyberKnife((R)) is the world,s ... of high-dose radiation with extreme accuracy throughout the body, including the brain, ...
... Medicaid Savings Could Surpass $59 Billion , , ... to reach an additional 20 million patients as part of national health ... the ten-year period 2010 to 2019, including federal Medicaid savings of $59 ... of the health center investment of $38.8 billion called for in the ...
Cached Medicine News:Health News:Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States 2Health News:Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States 3Health News:Joint Commission Recognizes Spectrum Healthcare Resources 2Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 2Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 3Health News:Vigilan Earns Honor in the 2009 Product & Technology Awards Program by Mature Market Resource Center 2Health News:St. Luke's Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 2Health News:St. Luke's Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 3Health News:Increasing Health Center Capacity by 20 Million Patients Could Save More Than $200 Billion Over the Next Decade 2Health News:Increasing Health Center Capacity by 20 Million Patients Could Save More Than $200 Billion Over the Next Decade 3
(Date:8/22/2014)... - On Aug. 20, at its annual meeting in ... (CMA) voted on and approved a delegate resolution opposing ... Bedrocan Cannabis Corp., a leading Canadian licensed producer of ... The CMA is quite right to point out ... plant material, including medicinal cannabis. While some patients, particularly ...
(Date:8/22/2014)... Research and Markets  has announced the addition of ... Technologies" report to their offering. ... you wish to expand your product line, you,ll know ... authors know you want to make effective product development ... improved revenues and take market share from your competition. ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... 2011 EMKinetics, Inc. announced today initiation of ... trial for patients suffering from urge incontinence and ... at 10-15 US centers.  Submission for CE mark ... the study.   EMKinetics, TranStim therapy builds on ...
... 2011 Masimo (NASDAQ: MASI ) announced ... period ended October 1, 2011, after the market closes on October ... at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted ... de Raad, Executive Vice President and Chief Financial Officer. ...
Cached Medicine Technology:EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 3
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein A - 12 OD...
Medicine Products: